Alzamend Neuro Inc (ALZN)

Mar 30, 2025

Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Update - Defense World

Mar 30, 2025

Mar 28, 2025

Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March? - Insider Monkey

Mar 28, 2025

Mar 27, 2025

Alzamend neuro director William Horne buys $3,285 in common stock By Investing.com - Investing.com Australia

Mar 27, 2025

Mar 27, 2025

Alzamend neuro director William Horne buys $3,285 in common stock - Investing.com India

Mar 27, 2025

Mar 26, 2025

Alzamend Neuro director Milton Ault buys $2,968 in company stock - Investing.com India

Mar 26, 2025

Mar 25, 2025

Alzamend Neuro director Milton Ault buys $2,968 in company stock By Investing.com - Investing.com South Africa

Mar 25, 2025

Mar 25, 2025

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital - The Manila Times

Mar 25, 2025

Mar 25, 2025

Major Breakthrough: New Alzheimer's Drug Advances to Phase II at Top Hospital - Stock Titan

Mar 25, 2025

Mar 24, 2025

Alzamend Neuro CFO David Katzoff acquires $5,048 in common stock By Investing.com - Investing.com Australia

Mar 24, 2025

Mar 24, 2025

Alzamend Neuro CFO David Katzoff acquires $5,048 in common stock - Investing.com

Mar 24, 2025

Mar 20, 2025

Alzamend Neuro director William B. Horne purchases $4,891 in shares - Investing.com India

Mar 20, 2025

Mar 20, 2025

Alzamend Neuro director William B. Horne purchases $4,891 in shares By Investing.com - Investing.com UK

Mar 20, 2025

Mar 20, 2025

Alzamend Neuro director William B. Horne buys $4,851 in stock - Investing.com India

Mar 20, 2025

Mar 19, 2025

Alzamend Neuro director William B. Horne buys $4,851 in stock By Investing.com - Investing.com South Africa

Mar 19, 2025

Mar 19, 2025

Alzamend Neuro director Milton C. Ault III acquires $4,810 in shares - Investing.com Australia

Mar 19, 2025

Mar 18, 2025

Alzamend Neuro director Milton C. Ault III acquires $4,810 in shares By Investing.com - Investing.com South Africa

Mar 18, 2025

Mar 18, 2025

Alzamend Neuro, Inc. Plans Phase II Clinical Study of AL001 in Major Depressive Disorder to Compare Lithium Delivery with Marketed Products - Nasdaq

Mar 18, 2025

Mar 18, 2025

Alzamend Neuro Announces Initiation Date of Phase II - GlobeNewswire

Mar 18, 2025

Mar 18, 2025

Major Depression Breakthrough: New Lithium Treatment Heads to Phase II at Top Hospital - StockTitan

Mar 18, 2025

Mar 17, 2025

Alzamend Neuro (ALZN) Projected to Post Earnings on Monday - Defense World

Mar 17, 2025

Mar 15, 2025

Alzamend Neuro director Milton Ault buys $68 in stock By Investing.com - Investing.com Australia

Mar 15, 2025

Mar 14, 2025

Alzamend Neuro director Milton Ault buys $68 in stock - Investing.com

Mar 14, 2025

Mar 13, 2025

Short Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Rises By 332.2% - Defense World

Mar 13, 2025

Mar 11, 2025

Alzamend Neuro stock hits 52-week low at $0.68 amid sharp decline - Investing.com Australia

Mar 11, 2025

Mar 11, 2025

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital - BioSpace

Mar 11, 2025

Mar 11, 2025

Alzamend Neuro stock hits 52-week low at $0.68 amid sharp decline By Investing.com - Investing.com South Africa

Mar 11, 2025

Mar 11, 2025

Alzamend Neuro plans mid-stage study of its therapy for PTSD in fourth-quarter 2025 - Marketscreener.com

Mar 11, 2025

Mar 11, 2025

Major PTSD Breakthrough: New Lithium Treatment Heads to Phase II Trial at Top Hospital - StockTitan

Mar 11, 2025

Mar 11, 2025

EXCLUSIVE: Alzamend Neuro To Launch Phase 2 Study For Lead Drug For PTSD Patients In Late 2025 To Assess Lithium Delivery Benefits - Benzinga

Mar 11, 2025

Mar 10, 2025

Alzamend Neuro Inc. (ALZN) reports earnings - Quartz

Mar 10, 2025

Mar 05, 2025

Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Down 33.0% in February - Defense World

Mar 05, 2025

Mar 04, 2025

Alzamend Neuro Announces Initiation Date Of Phase II Clinical Trial Of AL001 For Treatment Of Bipolar Disorder To Take Place At Massachusetts General Hospital - Marketscreener.com

Mar 04, 2025

Mar 04, 2025

Alzamend Neuro announces initiation date of Phase II trial of AL001 - TipRanks

Mar 04, 2025

Mar 04, 2025

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital - The Manila Times

Mar 04, 2025

Mar 04, 2025

Alzamend Neuro Announces Phase II Clinical Study of AL001 for Bipolar Disorder Expected to Start in Q3 2025 - Nasdaq

Mar 04, 2025

Mar 04, 2025

Alzamend Neuro Plans Phase II Trial for Advanced Lithium Treatment in Bipolar Disorder | ALZN Stock News - StockTitan

Mar 04, 2025

Mar 03, 2025

Alzamend Neuro Announces Bylaws Amendment and New Stock Series By Investing.com - Investing.com South Africa

Mar 03, 2025

Mar 03, 2025

Alzamend Neuro Announces Bylaws Amendment and New Stock Series - Investing.com

Mar 03, 2025

Mar 01, 2025

Alzamend Neuro stock hits 52-week low at $0.81 amid sharp decline - Investing.com Australia

Mar 01, 2025

Feb 28, 2025

Alzamend Neuro inks deal for equity securities sale By Investing.com - Investing.com South Africa

Feb 28, 2025

Feb 28, 2025

Alzamend Neuro inks deal for equity securities sale - Investing.com

Feb 28, 2025